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ABSTRACT To elucidate the mechanisms of cooperativity of cytochrome P450eryF an SH-reactive ﬂuorescent probe was
introduced close to the substrate-binding site. Cys-154, the only accessible cysteine, was eliminated by site-directed
mutagenesis, and a novel cysteine was substituted for Ser-93 in the B9/C loop. S93C, C154A, C154S, S93C/C154A, and S93C/
S154C were characterized in terms of afﬁnity for 1-pyrenebutanol (1-PB), cooperativity, and ionic-strength dependence of the 1-
PB-induced spin shift. S93C/C154S retains the key functional properties of the wild-type, and modiﬁcation by three different SH-
reactive probes had little effect on the characteristics of the enzyme. The labeled proteins exhibited ﬂuorescence resonance
energy transfer from 1-PB to the label, which allowed us to resolve two substrate-binding events, and to determine the
corresponding KD values (KD1 ¼ 1.2 6 0.2 mM, KD2 ¼ 9.4 6 0.8 mM). Using these values for analysis of the substrate-induced
spin transition, we demonstrate that the interactions of P450eryF with 1-PB are consistent with a sequential binding mechanism,
where substrate interactions at a higher-afﬁnity site cause a conformational transition crucial for the binding of the second
substrate molecule and subsequent spin shift. This transition is apparently associated with an important rearrangement of the
system of salt links in the proximity of Cys-154.
INTRODUCTION
In the last decade homo- and heterotropic cooperativity have
emerged as important properties of a number of cytochromes
P450, including human 3A4, 2C9, 1A2, 2D6, and 2B6 (1–4).
The most prominent examples of cooperativity are provided
by P450 3A4, the most abundant P450 in human liver (2).
Despite extensive studies, a generalized mechanism of this
apparent allostery is still missing. Starting from the work of
Korzekwa and co-authors (5,6) and Guengerich and co-
authors (7) the prevailing hypothesis is that cytochromes
P450 exhibiting cooperativity accommodate multiple sub-
strate molecules in one large binding pocket. A loose ﬁt of
a single substrate molecule requires the binding of a second
ligand for efﬁcient binding and/or catalysis (6,8). However,
the possibility that P450 cooperativity reﬂects a true case of
allostery, involving an effector-induced conformational tran-
sition in the enzyme has also been discussed extensively
(7,9–12). In this case, an effector-binding site might be
remote from the active site (7). Observation of distal binding
sites for palmitic acid in P450 2C8 (13) and for progesterone
in P450 3A4 (14) in recently resolved x-ray structures
provides important support for this possibility.
Studies of mutual effects of different substrates and effec-
tors of P450 3A4 have compelled some authors to suggest
three or more ligand binding sites in this enzyme (15–18),
although direct physical evidence is lacking. The situation
becomes even more complex when various indications of
conformational heterogeneity of P450 3A4 are incorporated
into mechanisms of cooperativity (11,19–21), leading to
a nested allostery model for this enzyme (10). This model,
which is based on the presumption of two stable conformers,
each possessing the properties of an allosteric enzyme with
twobinding sites,may provide a viable alternative to a scheme
with three ormore binding sites. Formation of P450 oligomers
in themicrosomalmembrane and in reconstituted systems has
been proposed as one explanation for such persistent confor-
mational heterogeneity (11). Therefore, understanding of the
mechanisms of cooperativity in P450 has exhibited a stepwise
transition from simple ‘‘space-ﬁlling’’ models (6,8) to more
dynamic and complex schemes. Accordingly, the current
concept of P450 cooperativity tends to approach classical
models of allosteric enzymes involving effector-induced con-
formational transitions in the enzyme and, possibly, modula-
tion of its oligomerization state.
Awareness of the increasing complexity of P450 cooper-
ativity necessitates novel approaches and experimental
techniques in the ﬁeld. Unfortunately, the analysis of P450
cooperativity from steady-state kinetics of substrate oxidation
cannot provide any information on the connection between
the binding of substrates and effectors and subsequent con-
formational transitions in the enzyme. Of particular impor-
tance is the relationship between the binding of each substrate
and/or effector molecule and the spin equilibrium of the heme
iron, which is thought to be an important determinant of
catalytic efﬁciency and coupling (22–27). Thus, to distin-
guish between different models of cooperativity and to
understand molecular mechanisms of modulation of P450
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activity by allosteric ligands it is critical to be able to monitor
enzyme-ligand interactions directly.
To establish such an approach we made use of cytochrome
P450eryF (P450 107A1) from Saccharopolyspora erythraea
as a model. P450eryF exhibits homotropic (28,29) and
heterotropic (30) cooperativity with such substrates as and-
rostenedione, testosterone, 7-benzoxyquinoline, a-naphtho-
ﬂavone, and pyrene derivatives (12,29–32). This soluble
bacterial enzyme lacking the complexity of membranous
monooxygenase systems provides a valuable reference point
for further studies of eukaryotic cytochromes P450. In our
initial experiments 1-pyrenebutanol (1-PB)was introduced as
a ﬂuorescent substrate of P450eryF (29). Interactions with 1-
PBwere monitored by the substrate-induced spin shift as well
as by ﬂuorescence resonance energy transfer (FRET) from the
substrate to the heme of the enzyme. The results suggest that
the binding of 1-PB to the higher-afﬁnity binding site alone
does not modulate the spin equilibrium, which is observed
only in the complex of P450with twomolecules of 1-PB (29).
This conclusion also appears to be valid for P450 3A4, based
on recent studies of the testosterone-induced spin shift in
monomeric P450 3A4 incorporated into a nanoscale lipid
bilayer (Nanodisks) (33), as well as studies of the effect of
interactions with testosterone and a-naphthoﬂavone on the
tryptophan ﬂuorescence of the enzyme (34). Further elabo-
ration of the mechanism of P450 cooperativity clearly re-
quires a similar direct approach to assess KD at the second
(lower-afﬁnity) binding site, which is essential to assess the
relevancy of any particular model of enzyme-substrate in-
teractions.
Furthermore, our recent studies of the effect of ionic
strength on P450eryF revealed a rearrangement of intra-
molecular electrostatic interactions in the proximity of
Cys-154 as an important element of the mechanisms of
cooperativity (12). The results indicate that the modulation
of the degree of hydration of the P450 heme pocket plays an
important role in allostery. Further exploration of this
hypothesis would be greatly facilitated by knowledge of the
dynamics of protein-bound water in the interactions of
P450eryF with allosteric ligands. Perturbation of protein-
ligand interactions by hydrostatic pressure provides a unique
approach to unravel the mechanisms of protein transitions
involving changes in interactions with the solvent (35–37).
Unfortunately, the quantum yield of the ﬂuorescence of
pyrenes and their spectral properties are known to be affected
by the formation of excimers, which is dependent on pyrene
concentration, viscosity of solution, polarity of the media,
hydrostatic and osmotic pressure, and temperature. Therefore,
techniques based on FRET from 1-PB to the heme of P450 are
not well suited for pressure perturbation experiments.
The objective of this study was to resolve the binding of
the ﬁrst and the second 1-PB molecules to P450eryF with
a more selective FRET-based assay involving a covalently
bound ﬂuorescent probe as an acceptor for FRET from the
substrate molecule. Of particular interest are SH-reactive
ﬂuorescent probes, since wild-type P450eryF contains only
two cysteine residues, namely Cys-154 and Cys-342. Only
Cys-154 is accessible to modiﬁcation, as Cys-342 serves as
a ligand to the heme iron. However, modiﬁcation of Cys-154
with 7-ethylamino-3-(49-maleimidylphenyl)-4-methylcou-
marin (CPM) had a crucial effect on the cooperativity and
spin equilibrium in P450eryF (12). Based on analysis of 3D
crystal structures of P450eryF we therefore introduced a new
cysteine residue in place of Ser-93 in the solvent-exposed
part of the B9/C loop. This residue is in the proximity of the
substrate-binding pocket, and the surface location was
expected to allow replacement with cysteine and modiﬁca-
tion by an appropriate SH-reactive probe without perturbing
the enzyme conformation. Incorporation of the label at Cys-
154 was prevented by replacement with alanine or serine.
Here we describe studies with P450eryF mutants bearing
various substitutions at position 154, together with a detailed
characterization of a double (S93C/C154S) mutant and its
derivatives labeled with SH-reactive probes, such as CPM,
N-[2-(1-maleimidyl)ethyl]-7-(diethylamino)coumarin-3-car-
boxamide (MDCC), and monobromobimane (mBBr). This
mutant retains the major properties of the wild-type enzyme,
and its modiﬁcation with CPM, MDCC, or mBBr has no
signiﬁcant effect on interactionswith 1-PB, substrate-induced
spin shift, or cooperativity. The binding of 1-PB to the labeled
mutant results in FRET to the ﬂuorescent probe, offering an
excellent tool for the studies of P450-ligand interactions.
This newly elaborated technique allowed us to resolve two
substrate-binding events and to determine the dissociation
constant for 1-PBbound at each of two sites in P450eryF. This
ﬁnding represents an advance in unraveling the relationship
between each of the substrate-binding events and the con-
formational transitions in the enzyme and on developing
a reliable model of cooperativity in cytochromes P450. In
addition to the results on enzyme-substrate interactions in the
labeled S93C/C154S mutant, we also provide a comparative
analysis of the effect of ionic strength on cooperativity and
spin transition in a series of P450eryFmutants at position 154,
which indicates that the mechanism of allostery involves a
ligand-induced conformational rearrangement in the vicinity
of Cys-154 that is associated with changes in the hydration of
this residue.
MATERIALS AND METHODS
Chemicals
CPM, MDCC, and mBBr were the products of Molecular Probes (Eugene,
OR). Oligonucleotide primers for PCR were obtained from Sigma Genosys
(Woodlands, TX). The QuikChange site-directed mutagenesis kit was from
Stratagene (La Jolla, CA). All other chemicals were of analytical grade and
used without further puriﬁcation.
Site-directed mutagenesis
All single mutants were generated using overlap extension PCR, and His-
tagged P450eryF (wild-type) as the template (31) and primers:
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In the latter primer, in addition to the main TGC/TGT replacement, we
made a silent GGC/GGT mutation to introduce an additional restriction
site. S93C/C154S and S93C/C154A double mutants were obtained using
S93C as the template and the same primers speciﬁed above for C154S and
C154A single mutants. All constructs were sequenced to ensure that only the
desired mutations were present (Protein Chemistry Core Laboratory, The
University of Texas Medical Branch, Galveston, TX).
Protein expression and puriﬁcation
P450eryF was expressed in Escherichia coli, and puriﬁed on a metal-afﬁnity
column, as described (31). All mutants produced nearly the same expression
levels as the wild-type P450eryF. Protein yields upon puriﬁcation varied
from 24 to 57%. Protein was stored at 80C in 0.1 M Na-Hepes buffer pH
7.4, 1 mM EDTA, and 1 mM dithiotreitol (DTT) containing 10% glycerol
(buffer A).
Preparation and characterization of P450eryF
labeled with ﬂuorescent probes
Before labeling of S93C/C154S P450eryF with SH-reactive ﬂuorescent
probes it was necessary to remove DTT present in the storage buffer (buffer
A, see above). The procedure of DTT removal was designed to prevent
oxidation of SH groups with possible formation of disulﬁde-linked protein
dimers. DTT was ﬁrst replaced by 2 mM Tris(2-carboxyethyl)phosphine
(TCEP), an SH-protecting agent. For this purpose, 250 ml of a concentrated
(400–600 mM) solution of protein was passed through Bio-Spin-6 column
(Bio-Rad Laboratories, Hercules, CA) equilibrated with 0.1 M Na-Hepes
buffer (Hepes()-buffer) containing 2 mM TCEP. Protein solution was then
diluted to 2.5 ml by argon-saturated Hepes() buffer and concentrated to
250 ml in an argon-ﬂushed Centrisart-I (cutoff 20,000) concentrator
(Sartorius AG, Goettingen, Germany). This dilution-concentration cycle
was then repeated. To modify this DTT-free preparation with CPM, MDCC,
or mBBr the sample containing 60–80 nmol of P450 was diluted to 20 mM
with argon-saturated Hepes()-buffer and incubated under argon gas at
constant stirring with a 1.2-fold molar excess of CPM, MDCC, or mBBr
added as a 2–3 mM solution in acetone-methanol (1:1, v/v). The reaction of
CPM,MDCC, and mBBr with the protein was followed by an increase in the
ﬂuorescence of the probes. The intensity of ﬂuorescence at 450–490 nm was
continuously monitored using an MC2000-2 rapid scanning spectrometer
(Ocean Optics, Dunedin, FL) with LED-380 light-emitting diode (Ocean
Optics) as a source of excitation light. Incubation for 5–6 h at 25C was
required for modiﬁcation of 95% of P450eryF S93C/C154S, as determined
by the ﬁtting of the kinetics of ﬂuorescence increase to the equation of
second-order reaction kinetics. When this level of modiﬁcation was reached,
the sample was concentrated to 250–300 ml on a Viva-Spin 4-ml 30,000
MWCO concentrator (Vivascience AG, Hannover, Germany) and trans-
ferred into buffer A by gel-exclusion chromatography on Bio-Spin-6 spin
column. Excess of the DTT-adduct of the label was then removed using
Cabiochem Detergent-Out hydrophobic absorber spin columns (EMD
Biosciences, La Jolla, CA).
Because the bands of absorbance of CPM (lmax¼ 385 nm), MDCC (lmax
¼ 419 nm) and mBBr (lmax ¼ 396 nm) overlap considerably with the Soret
bands of both low- and high-spin cytochrome P450, we used a special
technique to determine the exact degree of labeling. For this purpose the
sample of labeled P450eryF was treated with 60 mM hydrogen peroxide,
which causes destruction of the heme and complete disappearance of the
heme absorbance bands. This process was followed by repetitive measure-
ment of absorbance spectra in the 340–700 nm region. Complete
disappearance of the heme bands was achieved in 50–70 min of treatment.
The difference between the initial spectrum and the spectrum obtained after
complete bleaching was used to determine the exact concentration of P450
using known standard spectra of the low-spin, high-spin, and P420 states of
P450eryF (29). The amount of label was determined from the absorbance
spectrum of the bleached (heme-free) protein using the spectrum of a water
solution of glutathione adduct of the appropriate label as a standard. In these
determinations, we used our SpectraLab program (38) for linear least-square
ﬁtting of the spectra by a combination of spectral standards and a 1-to 2-
order polynomial, which was used to compensate for possible turbidity of
the media.
When used with MDCC and mBBr the above procedure of chemical
modiﬁcation of P450eryF S93C/C154S results in preparations with a molar
ratio of label to P450 of 0.8–1.0 and protein recovery as high as 80–90%.
In the case of modiﬁcation with CPM, the recovery of P450eryF after
modiﬁcation was ;50% due to a signiﬁcant content of labeled P450 apo-
protein (see Results), which was removed by ion-exchange chromatography
on D15X weakly cationic ion-exchange membrane adsorber (Sartorius
AG, Germany) as follows. The solution containing 40–50 nmol of P450eryF-
CPM obtained by the above procedure was diluted with nine volumes of
water and passed through a D15 membrane equilibrated with 10 mM Na-
Hepes buffer, pH 7.4, 1 mM DTT, and 1 mM EDTA. Passage of the sample
through the membrane was repeated until complete absorption of the
protein was achieved. The membrane was then washed with 20 ml of 0.1 M
Na-Hepes buffer, pH 7.4, 1 mM DTT, and 1 mM EDTA (Hepes(1)-buffer).
Further washing with 0.1 M KCl in the same buffer resulted in elution of
some amount (#3% of the initial amount of P450) of unmodiﬁed P450eryF.
P450eryF-CPMwas then eluted with 0.2 M KCl in Hepes(1) buffer. Further
washing of the membrane with 0.5 M KCl in the same buffer resulted in
elution of heme-free protein also bearing the CPM label. The CPM/P450
molar ratio in the sample eluted in 0.2 M KCl was determined to be 0.95–
1.0. This preparation was then concentrated to 150–200 mM P450 with a
Viva-Spin concentrator and transferred into buffer A using a Bio-Spin 6
column.
1-PB binding and FRET assays
The absorbance and ﬂuorescence spectra were measured with an MC2000-2
multichannel CCD rapid-scanning spectrometer (Ocean Optics) equipped
with one absorbance and one ﬂuorescence channel and a custom-made ther-
mostated cell chamber with a magnetic stirrer. L7893 UV–Vis ﬁber optics
light source (Hamamatsu Photonics, Tokyo, Japan). When the ﬂuorimetric
titrations were done with an MC2000-2 multichannel CCD rapid-scanning
spectrometer, a pulsed PX-2 Xe-lamp (Ocean Optics) with an interference
ﬁlter (53385, Oriel Instruments, Stratford, CT) having a transmittance band
with 10-nm bandwidth centered at 330 nm was used as a source of the
excitation light. The setup used in these FRET experiments permitted
simultaneous registration of the transmittance and ﬂuorescence spectra of
the same sample, which allowed instant correction of the spectra of ﬂuo-
rescence for the changes in the intensity of the excitation light during the
experiment. Alternatively, a computerized Hitachi F-2000 ﬂuorescence
spectrometer equipped with a custom-made thermostated cell holder and
a magnetic stirrer was used. In this case, the excitation wavelength was set to
331 nmwith a 10-nm bandwidth, and the ﬂuorescence emission spectra were
monitored in the region of 360–570 nmwith a 10-nm bandwidth. In this case
the spectra of absorbance of the sample taken before and after the experiment
were used to calculate apparent absorbance spectra at each particular point of
the titration, which were then used to correct the spectra of ﬂuorescence
for the changes in the intensity of the excitation light. All experiments
Mutation
DNA
positions Primer
C154A 447-474 59-CATCAAGGTCATCGCAGAGCTGCTCGGC-39
59-GCCGAGCAGCTCTGCGATGACCTTGATG-39
C154S 447-474 59-CATCAAGGTCATCTCTGAGCTGCTCGGC-39
59-GCCGAGCAGCTCAGAGATGACCTTGATG-39
S93C 263-292 59-CCAACATGGGTACCTGTGACCCGCCGACCC-39
59-GGGTCGGCGGGTCACAGGTACCCATGTTGG-39
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were done at 25C with continuous stirring in Hepes(1) buffer. The desired
ionic strength of the medium was achieved by addition of an appropriate
amount of KCl (as a 3-M stock solution in the Hepes buffer). An 8–15 mM
stock solution of 1-PB in acetone was used in our titration experiments.
The concentration of 1-PB in acetone solutions was determined by the
absorbance at 343 nm using the extinction coefﬁcient of 41,000 mM1 cm1
(39).
Data processing
The analysis of the series of spectra obtained in our spectrophotometric and
ﬂuorimetric titration/dilution experiments was done using a principal com-
ponent analysismethod,which is also knownas singular value decomposition
technique, as described earlier (38,40). To interpret the spectral transitions in
terms of the changes in the concentration of P450 species, we used a least-
squares ﬁtting of the spectra of principal components by the set of the spectral
standards of pure high-spin, low-spin, and P420 species of P450eryF (11). All
data treatment and ﬁtting, aswell as the data acquisitionwere performed using
our SpectraLab software package (38).
RESULTS
Effect of mutations at positions 93 and 154 on the
interactions of P450eryF with 1-PB and substrate-
induced spin shift
To introduce a unique accessible cysteine residue in close
proximity of the substrate-binding pocket of P450eryF, we
substituted Ser-93 with cysteine (S93C) and eliminated Cys-
154 by substitutionwith alanine or serine (C154A andC154S,
respectively). The newly obtainedmutantswere characterized
in terms of the interactions of the enzyme with 1-PB, co-
operativity, and the amplitude of the substrate-induced spin
shift, DFh, as well as the effect of ionic strength on the 1-PB-
induced spin shift and cooperativity. According to our recent
results (12), an increase in ionic strength augments consid-
erably the amplitude of the substrate-induced spin shift in
P450eryF. In the 0.01–0.6M range of ionic strength this effect
is correlated with a prominent decrease in the cooperativity of
the enzyme. The ionic strength dependence was characterized
quantitativelywith a semiempirical relationship similar to that
used by Peyser and co-authors to analyze the effect of ionic
strength on the conformation of myosin (41). Following this
approach, the fraction of the high-spin heme protein in the
enzyme-substrate complex (Fh) is represented as a function of
the degree of occupation of a putative ion-binding site in the
protein (41):
F
s
hðIÞ ¼ Fshð0Þ1 fFshðNÞ  Fshð0Þg3
½I=Kion
11 ½I=Kion; (1)
where [I] is the ion concentration (which is formally equi-
valent to the ionic strength in this context), Fh
s(I), Fh
s(0), and
Fh
s(N) are the high-spin fraction of P450 at ion concentration
[I], and at zero and inﬁnite ionic strength, respectively, and
Kion is the equilibrium constant of ion binding to a putative
ion binding site in the enzyme. Despite the evident over-
simpliﬁcations in this model, Eq. 1 ﬁts the experimental ionic
strength dependencies of Fh
s fairly well (see Fig. 2), pro-
viding a necessary starting point for a comparative analysis
of P450eryF mutants in terms of responsiveness to ionic
strength changes.
In Table 1, we compare the values of Kion, the constant of
spin equilibrium of the enzyme-substrate complex at I ¼ 0
(Kspin(0)), and the parameters of Hill equation (S50 and n) for
a series of P450eryF variants introduced in this study
together with the data on C154I and C154T mutants, which
were characterized earlier (29). Kspin(0) given in this table is
deﬁned as the ratio of concentrations of high- and low-spin
P450 states extrapolated to zero ionic strength:
Kspinð0Þ ¼ F
s
hð0Þ
1 Fshð0Þ
: (2)
For all mutants tested, the substrate dependencies of the
high-spin fraction of the enzyme obey the Hill equation with
a Hill coefﬁcient (n) indicative of positive cooperativity (Fig.
1, Table 1), which is consistent with that previously reported
for the wild-type enzyme (12,29). The replacement of Ser-93
with cysteine did not alter n and only slightly increased the
S50 for 1-PB. However, this mutation resulted in almost
a twofold decrease in the amplitude of the 1-PB-induced spin
shift. Similarly, the substitution of Cys-154 with alanine
caused a decrease in the amplitude of the 1-PB-induced spin
TABLE 1 Parameters of the interactions of P450eryF and its mutants with 1-PB
P450eryF variant S50, mM Hill coefﬁcient (n) DFh (%) Kion (mM) Kspin(0)
Wild-type (S93/C154) 7.9 6 1.1 2.1 6 0.2 29 6 5 850 0.25
C154I 13.2 6 1.8 1.4 6 0.2 21 6 4 1590 0.12
C154A 9.7 6 0.3 2.3 6 0.1 18 6 2 1140 0.19
C154T 9.2 6 0.1 1.8 6 0.1 21 6 3 1100 0.52
C154S 7.6 6 0.7 1.5 6 0.2 57 6 3 340 0.75
S93C 10.0 6 1.3 2.2 6 0.2 16 6 2 1190 0.14
S93C/C154S 8.4 6 0.7 2.2 6 0.2 41 6 1 450 0.81
S93C/C154A 12.1 6 0.2 2.4 6 0.4 9 6 1 2470 0.26
S93C-CPM /C154S 8.4 6 0.5 2.4 6 0.1 30 6 6 600 0.61
S93C-MDCC /C154S 10.2 6 1.0 1.7 6 0.3 31 6 3 1060 0.48
S93C-bimane/C154S 9.3 6 2.0 2.3 6 0.2 36 6 2 350 0.54
The parameters of 1-PB binding represent the averages of four individual measurements plus/minus conﬁdence intervals calculated for P ¼ 0.95. Parameters
of ionic strength dependence represent the results of a single measurement.
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shift, whereas both S50 and n remained unaffected. Re-
placement of Cys-154 with serine decreased the Hill
coefﬁcient, did not alter S50, and caused a twofold increase
in the amplitude of the spin shift.
The dependencies of the high-spin fraction in the substrate-
saturated enzyme on ionic strength are shown in Fig. 2. In both
S93C and C154A, the effect of ionic strength on the spin
equilibrium is largely suppressed, whereas C154S P450eryF
exhibits a considerably enhanced increase in the amplitude of
the substrate-induced spin shift at increased ionic strength.
Importantly, ﬁtting of the ionic strength dependencies of the
spin state for the wild-type P450eryF and each mutant gives
a value of the high-spin fraction at inﬁnite ionic strength
(Fh
s(N)) close to 100%. Averaging of Fh
s(N) obtained for all
P450eryF variants gives a value of 1016 11%. Therefore, at
inﬁnite ionic strength, where the ion tethers in the vicinity of
Cys-154 suggested in our previous study (12) are completely
released, the spin equilibrium in the substrate-bound enzyme
is completely shifted toward the high-spin state, regardless of
the nature of the amino acid residue at position 154.
Analysis of the data presented in Table 1 reveals an impor-
tant relationship among the values of S50, n,Kion, andKspin(0).
Comparison of the parameters obtained with various mutants
at position 154 exhibits a clear linear correlation between the
values of Kion and S50 (Fig. 3 a), so that the increase in Kion is
always accompanied by an increase in S50. In terms of our
hypothesis, this observation signiﬁes that an increase in the
strength of the strategic ion tethers around Cys-154 impedes
the interactions of P450eryF with 1-PB. Furthermore, the
changes in the value of Kspin(0) are strictly correlated with
those of the Hill coefﬁcient (Fig. 3 b). With the sole exception
of C154I any replacement of residue 154 that promotes the
formationof thehigh-spin stateof the substrate-boundP450eryF
at zero ionic strength results in decreased cooperativity of
the enzyme with 1-PB. Thus, although all substitutions of
residues 93 and 154 probed in our studies resulted inmoderate
alterations of the parameters of the interactions of the enzyme
with 1-PB, the main features observed with the wild-type
enzyme (12,29), namely positive cooperativity of 1-PB bind-
ing and a well-pronounced effect of ionic strength on the
1-PB-induced spin shift and cooperativity were retained.
The double mutants S93C/C154A and S93C/C154S reveal
additive effects of the single substitutions. S93C/C154A
exhibited a higher S50 and lowerDFh value than the wild-type
and each of the respective single mutants (Fig. 1, Table 1).
Similarly, the opposite changes in S50 and DFh values ob-
served in the respective single mutants were compensatory in
the S93C/C154S double mutant, which exhibited 1-PB-
binding parameters close to those of the wild-type. Impor-
tantly, both S93C/C154S and S93C/C154A double mutants
exhibited Hill coefﬁcients close to that of the wild-type
enzyme. The effect of the single mutations was also additive
with regard to the effect of ionic strength on the spin state of
the substrate-saturated enzyme. Due to such compensation of
the effects of single substitutions, S93C/C154S exhibited an
ionic strength dependency close to that of the wild-type (Fig.
2). Hence, we selected this mutant for further studies.
Labeling of S93C/C154S with SH-reactive probes
and characterization of the labeled enzyme
With MDCC and mBBr, the labeling procedure described in
Materials and Methods results in preparations with a label/
P450 molar ratio of 0.8–1.0 and protein recovery of ;80–
90%. However, in the case of CPM we observed partial
bleaching of the protein during its modiﬁcation, which
decreased the recovery of the labeled protein to ,50%. This
bleaching (heme loss) appears to be activated by light, as the
recovery of the labeled P450eryF-CPM was increased con-
siderably if the reaction was carried out in the dark without
ﬂuorimetric detection. Formation of a considerable amount
of labeled apo-protein required subsequent protein puriﬁca-
tion in this case (see Materials and Methods).
Detailed characterization of CPM-labeled S93C/C154S
P450eryF (P450eryF-CPM) in terms of 1-PB binding (Fig. 1,
Table 1) and the effect of ionic strength on the spin equi-
librium in the substrate-bound protein (Fig. 2) revealed that
covalent attachment of CPM to the mutant had little impact
on its characteristics. Parameters of the interactions of the
enzyme with 1-PB for P450eryF-MDCC and P450-bimane
FIGURE 1 1-PB binding to P450eryF mutants and CPM-labeled enzyme:
wild-type (s), S93C (d), C154S (,), C154A (;), S93C/C154S (h),
S93C/C154A (n), and CPM-labeled S93C/C154S mutant (P450eryF-CPM,
)). Conditions: 0.1 M Na-Hepes buffer, pH 7.4, 1 mM DTT, 1 mM EDTA,
and 2 mM enzyme, 25C.
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were very close to those of P450eryF-CPM (Table 1). Thus,
our data suggest that the labeling of S93C/C154S with CPM,
MDCC, or mBBr does not disturb the structure or confor-
mational dynamics of the enzyme, making the preparations
of P450eryF labeled with these probes suitable for further
mechanistic studies on enzyme-substrate interactions and
cooperativity.
Fluorescence resonance energy transfer in the
complexes of 1-PB with S93C/C154S P450eryF
labeled with ﬂuorescent probes
The CPM-labeled S93C/C154S P450eryF exhibited a bright
ﬂuorescence, having broad excitation and emission bands at
384 and 468 nm, respectively. In the case of P450eryF-
MDCC, a broad and asymmetric excitation bandwas centered
around 419 nm with the maximum of emission positioned at
492 nm. Although the intensity of ﬂuorescence of P450eryF-
MDCC was comparable to that of P450eryF-CPM, the ﬂuo-
rescence of P450eryF-bimane was considerably less intense.
In this case the maximum of excitation was found at 388 nm,
whereas the emission maximum was at 466 nm.
FRET in the complex of 1-PB with all three labeled
P450eryF preparations was probed by two alternative ap-
proaches. In the ﬁrst setup we titrated 0.3–0.6 mM 1-PB with
labeled protein at concentrations increasing from 0 to 20–25
mM. In this setup the maximal concentration of the complex
of the substrate with P450eryF was observed at high excess
of the enzyme over the substrate and, consistently, this
method was selective for the binding of 1-PB at the ﬁrst
(higher-afﬁnity) binding site. In the second setup, which we
designate as a dilution approach, a series of emission spectra
of the mixture of labeled protein with 1-PB were recorded at
a constant molar ratio and simultaneously changing concen-
trations. Obviously, when the enzyme and substrate were at
a 1:1 molar ratio, this approach was also selective for the
formation of a binary complex with substrate bound at the
higher-afﬁnity site.
In both the titration and dilution setups the changes in the
intensity of ﬂuorescence of the FRET donor (1-PB) and
acceptor (either CPM, MDCC, or bimane) were followed by
recording the spectra of emission from 360 to 600 nm. The
excitation wavelength was set at 331 nm. This wavelength,
which is close to the midpoint between two maxima of
excitation of 1-PB (327 and 343 nm), ensures minimal direct
excitation of all three ﬂuorescent probes.
In all experiments the concentration of the enzyme changes
considerably during the experiments. Although the absor-
bance of P450 at the excitation wavelength is low (e331 ﬃ
25,000 M1 cm1 for the low-spin P450eryF), these experi-
ments required careful correction of the intensity of the
excitation light during the titration (see Materials and
FIGURE 2 Effect of ionic strength on the high-spin content in the 1-PB-bound P450eryF wild-type, its mutants, and labeled derivatives. (a) Data obtained
with the wild-type enzyme (s), S93C (d), C154S (n), C154A (:), S93C/C154S (h), and S93C/C154A (n). (b) Results of the experiments with S93C/C154S
labeled with CPM (d), MDCC (n), and mBBr (¤). The curves characterizing P450eryF wild-type (s) and its unlabeled S93C/C154S mutant (h) are also
shown in this panel for comparison. In these experiments, the ionic strength was adjusted by addition of 3 M KCl in Hepes buffer. The concentration of 1-PB
was 40 mM. Other conditions were as in Fig. 1.
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Methods). In the case of titration of substrate by labeled
protein it was also necessary to correct the spectra for direct
excitation of FRET acceptors (CPM, MDCC, or bimane) by
subtraction of the ﬂuorescence of a corresponding concen-
tration of labeled P450eryF taken alone. This correction is less
critical in the case of MDCC, as the intensity of ﬂuorescence
of this label upon excitation at 331 nm is considerably lower
than that observed with CPM and bimane. Thus, MDCC
ensures the highest accuracy of FRET measurements in the
titration setup.
Although the comparison of the parameters of 1-PB
interactions with three labeled proteins (Table 1) suggests
that P450eryF-mBBr represents the best approximation of
the properties of the native enzyme, the low efﬁciency of
FRET in P450eryF-bimane complicates studies by static
ﬂuorescence techniques. The properties of the other two
labeled proteins, P450eryF-CPM and P450eryF-MDCC, are
quite similar to each other. However, the above-mentioned
advantages of the MDCC probe, together with our pre-
liminary results indicating that, of the three probes tested,
P450eryF-MDCC exhibits the lowest sensitivity of ﬂuores-
cence of the label to hydrostatic pressure, prompted us to
choose P450eryF-MDCC for the main part of these studies.
Determination of KD for 1-PB molecule bound at
high-afﬁnity binding site
Results of the studies of the interactions of P450eryF-MDCC
with 1-PB monitored by FRET using dilution of a 1:1
enzyme-substrate mixture are exempliﬁed in Fig. 4. The
spectra shown are normalized to the enzyme concentration,
so that in the absence of FRET the spectra are not expected to
be affected by the concentration of the mixture. As shown in
Fig. 4 a, increasing concentrations of the enzyme-substrate
mixture result in changes that are indicative of FRET from
1-PB to MDCC, namely a decrease in the intensity of the
1-PB emission bands located at 378, 396, and 412 nm, con-
comitant with an increase in the intensity of the emission
band of P450eryF-CPM (lmax ¼ 468 nm). Correspondingly,
application of principal component analysis to this series of
spectra yields the ﬁrst principal component, which reﬂects
these alterations (Fig. 4 b, long-dashed line) and covers over
99.5% of the total changes in the spectra of ﬂuorescence
observed here. The dependence of the amplitude of FRET
given by the loading factor for the ﬁrst principal component
on the concentration of P450eryF-CPM (Fig. 4 a, inset)
obeys a canonical equation for the equilibrium of formation
of enzyme-substrate complex at comparable concentrations
of interacting species (42; see page 73, Eq. II-53):
23½ES ¼ ½E01 ½S01KD
 fð½E01 ½S01KDÞ2  43½E03½S0g1=2 : (3)
Similar results were obtained with the other two labels,
although P450eryF-CPM exhibits a KD value of 0.70 6 0.3
mM, which is slightly lower than the values obtained with
P450eryF-MDCC and P450eryF-bimane (1.24 6 0.1 and
1.21 6 0.3 mM, respectively). Fig. 4 b compares the spectra
of FRET given by the ﬁrst principal component derived from
the dilution experiments with all three different labels used in
this study. The highest increase of ﬂuorescence of the
acceptor ﬂuorophore is observed with CPM (Fig. 4 b, solid
line), whereas in the case of MDCC and bimane (long- and
short-dashed lines, respectively) the changes in the ﬂuores-
cence of acceptor are smaller. This is consistent with less
overlapping of the band of absorbance of the acceptor with
the band of emission of the donor (1-PB) for the latter two
labels. Although the absorbance band of CPM (lmax ¼ 385
FIGURE 3 Cross correlation between the parameters of 1-PB binding and the effect of ionic strength on the spin equilibrium for a series of P450eryF
variants with substitutions at position 154. (a) S50 versus Kion. (b) Hill coefﬁcient, n, versus Kspin(0).
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nm) completely overlaps with the main bands of 1-PB
emission at 379 and 398 nm, the absorbance band of MDCC
is shifted considerably toward longer wavelength (419 nm),
which decreases the efﬁciency of FRET to this donor. Al-
though the band of absorbance of bimane (lmax ¼ 388 nm)
has a position close to that of CPM, it is characterized by
a very low extinction coefﬁcient (e388 ¼ 5000 M1 cm1, as
compared to e385 ¼ 33,000 M1 cm1 and e319 ¼ 50,000
M1 cm1 characteristic of CPM and MDCC, respectively
(39), which results in lower efﬁciency of FRET in the 1-PB/
bimane pair than 1-PB/CPM and 1-PB/MDCC.
Similar results were also obtained upon studies of
P450eryF-CPM interactions with 1-PB in the titration setup.
Titrations of 1-PB with P450eryF-MDCC, P450eryF-CPM,
and P450-bimane exhibit changes in ﬂuorescence indicative
of FRET from 1-PB to the acceptor ﬂuorophore (data not
shown). Consistent with the results found by the dilution
approach, the concentration dependency of the intensity of
FRET given by the loading factor of the ﬁrst principal com-
ponent obeys the equation for the equilibrium of binary
complex formation (Eq. 3). These experiments yield the
values of 1.06 0.1, 1.46 0.4, and 0.836 0.3 for P450eryF-
CPM, P450eryF-MDCC and P450eryF-bimane, respec-
tively. The fact that all three labeled preparations of the
enzyme exhibit similar KD values in both dilution and
titration setups suggests that the nature of the label has
a negligible impact on the interactions of the enzyme with
1-PB.
It should be noted that the dilution setup is preferable for
determination of KD by FRET, since no correction for direct
excitation of the acceptor is required. However, this ap-
proach does not provide an accurate estimate of the ampli-
tude of FRET, as the series of spectra obtained in the dilution
setup lacks the point corresponding to the absence of ac-
ceptor. The efﬁciency of FRET estimated from the maximal
decrease in 1-PB emission in the titration experiments with
P450eryF-CPM and P450-MDCC was estimated to be of
98 6 5 and 71 6 11%, respectively.
The mean of the results of all experiments in either
dilution or titration setups with all three labeled P450eryF
preparations gives a KD of 1.2 6 0.2 mM, which is fairly
consistent with the value of 2.1 6 0.8 mM reported in our
earlier study for the interaction of 1PB with the wild-type
enzyme detected by FRET to the heme (12,29). The dif-
ference in these estimates may reﬂect the effect of C154S and
S93C replacements, the impact of chemical modiﬁcation of
the enzyme, or the presence of hydroxypropylcyclodextrin in
the reaction media in our earlier experiments. This compound
may increase the value of KD due to association with 1-PB,
and was omitted in this study.
FIGURE 4 Determination of KD of the complex of labeled P450eryF S93C/C154S with 1-PB bound at the high-afﬁnity binding site by FRET in a dilution
setup. (a) Normalized emission spectra of an equimolar mixture of P450eryF with 1-PB at 0.23, 0.9, 1.4, 2.6, 3.4, 4.9, 7.6, 11, 13, and 16 mM P450eryF-
MDCC. Intensity of ﬂuorescence is expressed in arbitrary units (a.u.). The inset shows the results of the same experiment as the plot of the amplitude of FRET
given by the loading factor of the ﬁrst principal component versus the concentration of P450eryF-MDCC. The solid line shows the approximation of this data
set by Eq. 3 with KD ¼ 1.2 mM. Conditions were as in Fig. 3. (b) The spectra of the ﬁrst principal component derived from the experiments with equimolar
mixtures of 1-PB with P450eryF-CPM (solid line), P450eryF-MDCC (long-dashed line), and P450eryF-bimane (short-dashed line).
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Determination of KD for 1-PB molecule bound at
the low-afﬁnity binding site
Although the studies of the interactions of P450eryF with
1-PB by dilution of a 1:1 enzyme-substrate mixture are
speciﬁc for determination of KD at the ﬁrst (higher-afﬁnity)
binding site (KD1), dilution experiments at excess substrate
can be used to study substrate binding at a lower-afﬁnity site
provided that the higher-afﬁnity site is already saturated.
According to Eq. 3, at a threefold molar excess of the sub-
strate over the enzyme, 80% saturation of the higher-afﬁnity
site (KD ¼ 1.2 mM) is observed at an enzyme concentration
of 2 mM. Therefore, at the enzyme/substrate ratio of 1:3 or
higher and enzyme concentration above 2 mM, the high-
afﬁnity binding site may be considered as occupied by 1-PB,
so that FRET will reﬂect the binding at the second (lower-
afﬁnity) site only.
A series of spectra obtained in a FRET dilution experiment
with a mixture of P450eryF-MDCC with 1-PB taken at a 3.3-
fold molar excess is shown in Fig. 5 a. Here, similar to that
observed at a 1:1 molar ratio, increase in the concentration of
the enzyme-substrate mixture results in decrease in the
amplitude of the 1-PB emission band concomitant with an
increase in the ﬂuorescence of MDCC. The dependence of
the amplitude of FRET on the protein concentration obeys
Eq. 3, exhibiting a KD value of 8.6 6 0.3 mM. Importantly,
increase in the substrate/enzyme molar ratio has no dis-
tinguishable effect on the value of KD determined in this
way. Thus, the FRET dilution experiments carried out with
P450eryF-MDCC and 1-PB at a seven- or eightfold excess of
substrate gave a KD of 10.0 6 0.3 and 9.6 6 0.4 mM.
Averaging these results yields a value of 9.4 6 0.8 mM for
the dissociation constant for 1-PB binding at the low-afﬁnity
binding site, provided that the high-afﬁnity site is already
occupied by this substrate.
Fig. 5 b shows the ﬁrst principal component spectrum of
FRET in a 1:3.3 P450eryF-MDCC mixture with 1-PB
(dashed line) as compared to the spectrum obtained at a 1:1
enzyme-substrate ratio (solid line). With excess substrate the
amplitude of the MDCC emission band is considerably lower
than in the case of an equimolar enzyme-substrate mixture.
This lower efﬁciency of energy transfer to MDCC ﬂuo-
rophore suggests that the low-afﬁnity binding site is located
at a longer distance from MDCC (i.e., from Cys-93 residue
of the mutant) than the high-afﬁnity site.
Studies of the interactions of P450eryF-MDCC
with 1-PB by absorbance spectroscopy
The ability to resolve 1-PB interactions at each of two
binding sites and to determine the values of two dissociation
FIGURE 5 Determination of KD of the complex of labeled P450eryF S93C/C154S with 1-PB bound at the low-afﬁnity binding site by FRET in a dilution
setup. (a) Normalized emission spectra of a mixture of P450eryF with 1-PB taken at a 1:3.3 molar ratio at 3.6, 4.7, 5.8, 6.8, 10, 12., 15, 17, 21, 23, and 25 mM
P450eryF-MDCC. Intensity of ﬂuorescence is expressed in arbitrary units (a.u.). The inset shows the results of the same experiment as the plot of the amplitude
of FRET given by the loading factor of the ﬁrst principal component versus the concentration of P450eryF-MDCC. The solid line shows the approximation of
this data set by the equation for the equilibrium of bimolecular association with KD¼ 8.6 mM. Conditions were as in Fig. 3. (b) The spectra of the ﬁrst principal
component derived from the experiments with the mixtures of 1-PB with P450eryF-MDCC taken at a molar ratio of 1:3.3 (dashed line) and 1:1 (solid line).
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constants provided an important opportunity to reconsider
the relationship between the interactions of P450eryF with
substrates and the substrate-induced spin shift. A simple
calculation using Eq. 3 and KD1 of 1.2 mM shows that the
addition of an equimolar concentration of 1-PB to a 10 mM
solution of P450eryF-MDCC should result in 70% saturation
of the higher-afﬁnity site, whereas the second binding site
will remain vacant. Thus, titration of high ($10 mM) con-
centration of the enzyme with 1-PB up to a 1:1 enzyme/
substrate ratio may be used to probe the changes in the
absorbance spectrum of the enzyme caused by the binding of
the ﬁrst substrate molecule. Although the changes in the
absorbance spectrum of the enzyme observed in these
experiments were extremely small (Fig. 6 a), they revealed
a decrease in the amplitude of the Soret band of the low-spin
P450eryF concomitant with some broadening of this band
upon binding of the ﬁrst molecule of 1-PB. Attempts to
interpret these results in terms of the changes in concen-
trations of the low-spin and high-spin P450eryF species
show no change in the concentration of high-spin P450, but
an apparent decrease in concentration of the low-spin P450
(Fig. 6 a, inset). This apparent decrease reﬂects the changes
in the extinction coefﬁcient of the low-spin enzyme caused
by the binding of the ﬁrst molecule of 1-PB. Interestingly,
attempts to ﬁt the dependence of these changes on the
concentration of substrate to Eq. 3 (Fig. 6 a, inset) yields
a dissociation constant of 0.9 6 0.6 mM, which is consistent
with the value of KD1 determined in our FRET experiments
(1.2 6 0.2 mM). However, due to the very small amplitude
of the spectral signal and the lack of data for the close-to-
saturation region of 1-PB concentrations, the estimate from
absorbance spectra is rough and is useful mainly to assess the
qualitative consistency of these data with the results of FRET
experiments. In contrast, as stated above, the spectral changes
observed in the titration of low concentration (0.5–3 mM) of
P450eryF-MDCC with concentrations of 1-PB up to 40 mM
are indicative of a distinct substrate-induced spin shift
(Fig. 6 b).
Thus, these results conﬁrm our initial conclusion (29) that
the binding of the ﬁrst 1-PB molecule to P450eryF fails to
induce any changes in the spin equilibrium of the enzyme.
However, recently we demonstrated a prominent effect of
ionic strength on the substrate-induced spin shift and
cooperativity in P450eryF. To understand the relationship
between the effects of ionic strength and the binding of the
ﬁrst substrate molecule to the enzyme it was important to
perform experiments at higher salt concentrations. Therefore
we compared the effect of ionic strength on the spin equi-
librium in substrate-free P450eryF-MDCC withh the enzyme
completely saturated with 1-PB, and in P450-MDCC with
1-PB bound only to the high-afﬁnity binding site, which is
referred to below as semisaturated enzyme. The effect of salt
additions to a concentrated (11–13 mM) equimolar mixture
of P450eryF-MDCC with 1-PB is presented in Fig. 7.
Although the effect of ionic strength on the spin state of
substrate-free enzyme is rather small, addition of KCl to both
completely saturated and semisaturated enzyme results in
a prominent increase in the high-spin content. At 0.06 M
ionic strength (i.e., in 0.1 M Na-Hepes with no KCl added)
the content of the high-spin state (Fh) in the semisaturated
P450eryF-MDCC is similar to that in the substrate-free
enzyme (;13%). However, increase in ionic strength to 0.8
FIGURE 6 Changes in the spectra of absorbance of P450eryF-MDCC upon its interactions of 1-PB. (a) A series of the difference spectra derived from the
titration of 12.7 mMenzyme with 1-PB. The main panel shows the spectra obtained by subtraction of the spectrum of the substrate-free enzyme from the spectra
measured at 2.9 (long-dashed line), 5.8 (medium-dashed line), 8.6 (short-dashed line), and 11 mM (solid line) 1-PB. This experiment was done in a cell with an
optical path length of 5 mm. The inset shows the changes in the apparent concentration of the low-spin P450eryF derived from this experiment. The solid line
represents the results of the ﬁtting of this data set by Eq. 3 with KD¼ 0.9 mM. (b) A series of the difference spectra derived from the titration of 2.4 mM enzyme
with 1-PB. The main panel shows the spectra obtained by subtraction of the spectrum of the substrate-free enzyme from the spectra measured at 2.6 (solid line),
5.1 (long-dashed line), 7.2 (medium-dashed line), 10 (short-dashed line), 12 (dotted line),14 (dash-dotted line), 18 (dash-double-dotted line), and 23 mM (solid
line) 1-PB. The optical path length of the cell used in this experiment was equal to 10 mm. The inset shows the changes in the high-spin fraction of the enzyme
derived from this experiment. The solid line represents the results of the ﬁtting of this data set by Eq. 5 (see Discussion) with KD1 ¼ 1.2 and KD2 ¼ 8.5 mM.
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M increases the value of Fh to 35% in semisaturated enzyme,
but only to ;20% in the substrate-free P450. This ob-
servation suggests that the conclusion that the binding of one
1-PB molecule per molecule of P450eryF is insufﬁcient to
shift the spin equilibrium of the enzyme is strictly valid only
at low ionic strength. A conformational change in P450eryF
induced by increased ionic strength makes the ﬁrst substrate-
binding event capable of partial displacement of the spin
equilibrium. It is important to note that the shapes of the
ionic-strength dependencies of completely saturated (Fig. 7,
circles) and semi-saturated enzyme (Fig. 7, squares) are
remarkably similar, suggesting that the displacement of the
spin equilibrium in both states of the enzyme reﬂects the
same ionic-strength-dependent conformational transition.
DISCUSSION
In this study, we describe the P450eryF S93C/C154S
mutant, which reproduces the main properties of the wild-
type enzyme and can be modiﬁed by CPM, MDCC, and
mBBr with virtually no effect on the interactions with 1-PB.
Furthermore, the proteins exhibited an extensive FRET to the
label upon the binding of 1-PB. The main advantage of
FRET from 1-PB to a ﬂuorescent probe as compared to the
heme is that the formation of the enzyme-substrate complex
is accompanied by a simultaneous decrease in 1-PB ﬂuo-
rescence and increase in the ﬂuorescence of the acceptor
ﬂuorophore. This highly distinctive signal considerably
broadens the applicability of the method, especially in cases
where the intensity of ﬂuorescence of the pyrene ﬂuorophore
might be affected by excimerization of 1-PB or changes in
the turbidity or refractivity of the medium.
The labeled S93C/C154S preparations, and P450eryF-
MDCC in particular, provide an invaluable tool for resolution
of two substrate-binding events by FRET and determina-
tion of the values of KD1 and KD2 for substrate binding to
P450eryF. To our knowledge, this has not been accom-
plished previously with any allosteric P450. This important
result allows us to delineate a mechanistic model of the
cooperativity in substrate binding to P450eryF. The interac-
tions of substrate with two binding sites in cytochrome P450
and subsequent spin transitions can be represented schemat-
ically as follows:
: (4)
Here E stands for the substrate-free enzyme (P450eryF);
the complexes of the substrate bound at each of the two sites
are designated by ES and SE; SES stands for the ternary
complex with both binding sites occupied. KD1, KD2, KD3,
and KD4 are the dissociation constants. The diagonal arrows
show spin transitions, and ls and hs correspond to the low-
and high-spin P450, respectively. Kh
E, Kh
ES, Kh
SE, and Kh
SES
are the constants of spin equilibrium. To simplify the
analysis, we introduced an earlier model (29) that suggests
independent binding of two substrate molecules at two
binding sites. For simplicity we initially hypothesized that
substrate binding at each site has no effect on the interactions
at the second one, so that KD1¼ KD3, KD2¼ KD4. According
to this simpliﬁcation, the cooperativity revealed in the
substrate-induced spin shift is caused solely by the fact that
the displacement of the spin equilibrium is observed in the
ternary complex only. Our further studies showed that,
although this scheme adequately describes the behavior of
the enzyme at low ionic strength, it fails to ﬁt the data
FIGURE 7 Ionic-strength-induced changes in the content of the high-spin
state of P450eryF-MDCC in the enzyme saturated with 1-PB (s), and in
semisaturated (h) and substrate-free ()) enzyme . The resulting curves
were obtained by addition of KCl to a 2.6 mM solution of P450eryF-MDCC
with no substrate added ()) and to the mixtures of P450eryF-MDCC with
1-PB taken at concentrations of 2.9 and 40 mM (s) and 11 and 11 mM,
respectively. Solid lines represent the results of the ﬁtting of these data sets
by Eq. 1.
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obtained at increased salt concentration (12). Furthermore,
even in the cases where the experimental data satisfactorily
obey the equation derived from this model, ﬁtting of the
titration curves often gives a value of KD2 considerably lower
than the value of KD1 determined by FRET, which is inter-
nally inconsistent (12). This observation suggests that the
binding of the ﬁrst molecule of 1-PB to the enzyme may have
an important effect on substrate interactions at the second
site, in line with much of the current thinking about P450
cooperativity.
Another extreme case of a two-binding-site model is
sequential binding, where the binding at the second binding
site is impossible without saturation of the higher-afﬁnity
effector site. This model suggests that KD4  KD1 and KD3
 KD2, so that the pathways leading to the formation of SE
may be neglected. To simplify the analysis further, we
proceeded with the assumption that the modulation of the
spin equilibrium is observed in the ternary complex only and
Kh
E ¼ KhES. In the most general representation applicable at
comparable concentrations of the enzyme and the substrate,
the analysis of Scheme 4 with the above simpliﬁcations gives
the following relationship between the steady-state concen-
tration of the ternary complex ([SES]), that of the complex
ES ([ES]), and the total concentration of the enzyme and
substrate ([E]0 and [S0], respectively):
2 3 ½ES2  ð½E0  ½SES1KD1Þ 3 ½ES  ð½S01 2 3 ½E0
1KD2Þ 3 ½SES1 ½S0 3 ½E0 ¼ 0;
where
½ES ¼ ½S0
2
½SES ½SES2ð½S
0
1KD2Þ3½SES1 ½S
2
0
4
 1=2
:
(5)
Although analytical solution of this equation for [SES] is
intricate, it can be easily done by a numerical means. To ﬁt
the experimental data to the above relationship, we used the
nonlinear least-square-ﬁtting module of our SpectraLab pro-
gram (38).
Using this equation to ﬁt the experimental data on the 1-PB-
induced spin shift and ﬁxing the value ofKD1 to that found by
FRET, we can solve for KD2 to probe the consistency of the
above model. Using this approach, we found that Eq. 5
adequately ﬁts all curves of substrate-induced spin shift
obtained in this study. An example of such ﬁtting is shown in
the inset in Fig. 6 b. Crucial evidence of the applicability of
this model is given by the fact that the ﬁtting of the curves
obtained with different concentrations of P450eryF-MDCC
varying in the range of 0.6–13mMgive similar values ofKD2.
In these experiments, the mean value of KD2 was estimated to
be 10.86 1.7mM,which is consistent with the value of 9.46
0.8 mM found in our FRET dilution experiments. It is
important, that the above equation also provides good ﬁtting
for all titration experiments at increased ionic strength
obtained in our previous study (12) (data not shown). In this
case the value of KD2 is always higher than the value of KD1,
which eliminates the inconsistency in our initial simpliﬁca-
tion. Therefore, we may conclude that the binding of 1-PB at
the higher-afﬁnity (effector) binding site radically increases
the afﬁnity of the second binding site for this substrate.
Although the sequential binding model adequately describes
all data obtained in our experiments, the real situation may be
intermediate between the two suggestedmodels, being closer,
however, to the sequential binding scheme.
Studying the relationship between substrate binding at each
of the sites and the substrate-induced spin shift we found that
the binding of the ﬁrst 1-PBmolecule has no effect on the spin
equilibrium of the enzyme at low ionic strength. Instead, these
interactions induce a slight but clearly detectable change in
the absorbance spectrum of P450eryF, which is reﬂected in
a decrease in the amplitude and broadening of the Soret band
of the low-spin enzyme. These changes apparently reﬂect
changes in the conformation and/or degree of hydration of the
heme pocket caused by the binding of the ﬁrst 1-PBmolecule.
However, this conclusion appears to be strictly correct only
at low ionic strength of the media. As shown in Fig. 7, an
increase in salt concentration results in considerable dis-
placement of the spin equilibrium of semisaturated enzyme
toward the high-spin state. Thus, an ionic-strength-induced
conformational transition in the enzyme makes the ﬁrst
substrate-binding event capable of modulation of the spin
equilibrium. This may happen either by promoting the for-
mation of the ES complex (thus compromising the sequential
binding scheme), or by making the formation of the SE com-
plex sufﬁcient to modulate the spin equilibrium. Therefore,
the decrease in cooperativity observed at increased ionic
strength (12) is partially due to the fact that the binding curves
for the substrate-induced spin shift at high ionic strength
represent the sum of the concentration of the SES, SE, and/or
ES complexes.
The above analysis strongly supports the point of view
that the phenomenon of cooperativity in P450eryF is based
on an effector-induced conformational transition and there-
fore represents a case of true allostery. In our recent study
(12), we presented evidence that this mechanism is based on
the dynamics of ion tethers in the vicinity of Cys-154, which
determine the conformation of a functionally important cleft
formed by a-helices D, E, F, and G and the respective in-
terhelical loops (Fig. 8). Our results obtained with P450eryF
mutants in this study allow us to further reﬁne this concept.
The clear positive linear correlation between the values of
Kion and S50 (Fig. 3 a) suggests that an increase in the
strength of the strategic ion tethers around Cys-154 (Fig. 8)
impedes the interactions of P450eryF with 1-PB. Further-
more, the changes in the value of Kspin(0) are strictly
correlated with those of the Hill coefﬁcient (Fig. 3 b). With
the sole exception of C154I, any replacement of residue 154
that promotes the formation of the high-spin state of the
substrate-saturated P450eryF at zero ionic strength results in
decreased cooperativity of the enzyme with 1-PB.
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To delineate the relationship between the substrate-
induced spin shift and cooperativity and the parameters of
residue 154 we analyzed the correlation of S50, n, Kion, and
Kspin(0) with such physicochemical properties of this residue
as bulkiness, polarity, and hydrophobicity given by several
different scales. The correlation was characterized by values
of Pearson product-moment correlation coefﬁcient (r).
Among the probed scales the best correlation was found
between polarity characterized by the free energy of transfer
of the side chain from cyclohexane to water (DGw) (43) and
Kspin(0) (r ¼ -0.98). Similarly, considerable correlation was
found between DGw and the Hill coefﬁcient for the set of all
considered P450eryF mutants except C154I (r ¼ 0.96). DGw
also reveals a noticeable correlation with the values of S50
and Kion (r ¼ 0.76 in both cases). As the value of DGw
characterizes the ability of the side chain to form hydrogen
bonds and to interact with water, we may infer that the
conformational transition in P450eryF caused by the binding
of 1-PB to the effector-binding site promotes a substrate-
induced spin shift by a mechanism that implicates the
formation of a hydrogen bond involving Cys-154 and/or
relocation of some protein-bound water molecule(s) in the
proximity of this residue. This change is facilitated when
a more polar residue replaces Cys-154, as in C154S. Hence,
the requirement for the binding of the substrate to both
effector and substrate-binding sites for a substrate-induced
spin shift in P450eryF is compromised and cooperativity is
decreased. Only C154I deviates from this rule. The coopera-
tivity displayed by this mutant is unusually low, despite the
fact that DGw of isoleucine is very high, and, consequently,
the mutant exhibits a very low value of Kspin(0). This result
might be explained by a speciﬁc effect of Cys-154 replace-
ment by the bulky and hydrophobic isoleucine residue on the
structure of the enzyme (12).
In addition, the values of S50, and Kion reveal a correlation
with the bulkiness of the side chain (44) of residue 154 (r ¼
0.81 and r¼ 0.87, respectively). Thus, the highest afﬁnity of
P450eryF to 1-PB is observed with the mutants bearing small
and polar residues at this position. Hence it appears that the
binding of 1-PB to the substrate-binding site of P450eryF
is facilitated by increased conformational mobility in the
vicinity of Cys-154, which is required for a substrate-induced
conformational transition of the enzyme.
Assessment of the exact structural relevance of the above
inferences is complicated by the lack of a substrate-free
P450eryF structure. However, some idea on conformational
dynamics of the enzyme in the proximity of Cys-154 may be
derived from the comparative analysis of the available x-ray
structures of P450eryF complexes with different substra-
tes—deoxyerythronolide B (6-DEB, Protein Data Bank
entries 1oxa and 1jio) (28,45), ketoconazole (entry 1jip)
(28), 9-aminophenanthrene (1egy), and androstenedione
(1eup) (46). In Fig. 8, we compare the structure of this
region in P450eryF complexes with its natural substrate 6-
deoxyerythronolide B, 6-DEB (1jio) and with ketoconazole
(1jip).
In all known structures of P450eryF, the distance between
the sulfur atom of Cys-154 and the epsilon nitrogen atom of
Arg-164 is within 3.5–4.0 A˚. This observation suggests
formation of a SNH hydrogen bond, the typical length of
which is known to be 3.1–3.9 A˚ (47–49). The latter arginine
residue participates in a salt link only in 1jio, forming a salt
FIGURE 8 Models of part of the crystal structures of the complexes of P450eryF with 6-DEB (left) and ketoconazole (right) (28) showing putative charge-
pairing contacts in the vicinity of Cys-154, the side chain of which is shown in yellow as a space-ﬁlling model. Space ﬁlling models also designate Ser-93
(magenta), heme (gray), and substrate (either 6-DEB or ketoconazole) (pale green). Red and green stick models show acidic and basic amino acid residues
participating in salt links.
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bridge with Asp-160. In all other structures, Asp-160
interacts with Arg-202, whereas in 1jio this important tether
between the E/F loop and the G-helix is formed by the Glu-
161/Arg-202 pair (Fig. 8). As a result of this rearrangement,
the conformation of the E/F loop and the position of
a-helices F and G relative to helices D and E in 1jio differ
from those observed in other structures (Fig. 8). It is
important to note that the structures of P450eryF complexes
with 6-DEB (1jio and 1oxa) are the only ones displaying
a water molecule at the distal side of the heme moiety. This
water, which is 2.7 A˚ from the heme plane and 3.6 A˚ from
the iron atom in the 1jio structure, may potentially serve as
a heme ligand in the low-spin state of the enzyme-substrate
complex. Thus, taking into account that the polarity of
residue 154 correlates with both cooperativity and position
of spin equilibrium in P450eryF, we have good grounds to
believe that the Cys-154-Arg-164 H-bond has strategic
importance, and the dynamics of D160-R164, E161-R202,
and D160-R202 salt links is fundamental for the mechanisms
of spin transition and cooperativity in P450eryF.
Taken together, our results strongly support the point of
view that the cooperativity in cytochrome P450eryF repre-
sents a classical example of allostery, which involves a con-
formational transition of the enzyme induced by the binding
of the effector. Furthermore, the above analysis emphasizes
the importance of further exploration of the dynamics of salt
bridges and protein-bound water in P450eryF interactions
with substrates and allosteric effectors. We believe that fur-
ther study of the molecular mechanism of the ligand-induced
conformational transition in P450eryF by our new FRET-
based approach in combination with site-directed mutagen-
esis of salt-link-forming residues in proximity of Cys-154
(D160, E161, R164, and R202) and the pressure-perturbation
technique will provide us with further details crucial to un-
raveling the molecular mechanisms and understanding the
functional signiﬁcance of the cooperativity in cytochromes
P450.
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